Evidence map›Paper›PMID 31155409›Full record

ArticleClinical lymphoma, myeloma & leukemia2019

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

Amandeep Salhotra, Michelle Afkhami, Dongyun Yang, Sally Mokhtari, Milhan Telatar, Dongqing Gu, Raju K Pillai, Dennis D Weisenburger, Joyce Murata-Collins, Diana Weigel and 16 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 1 institution in 1 country.

Amandeep SalhotraDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA. Electronic address: asalhotra@coh.org.
Michelle AfkhamiDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Dongyun YangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA.
Sally MokhtariDepartment of Clinical Translational Program Development, City of Hope National Medical Center, Duarte, CA.
Milhan TelatarDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Dongqing GuDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Raju K PillaiDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Dennis D WeisenburgerDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Joyce Murata-CollinsDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Diana WeigelDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Patricia AounDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Ibrahim AldossDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Monzr M Al MalkiDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Samer KhaledDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Matthew MeiDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Haris AliDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Ahmed AribiDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Elizabeth BuddeDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Karamjeet SandhuDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Margaret O'DonnellDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
David SnyderDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Vinod PullarkatDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Stephen J FormanDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Guido MarcucciDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Ryotaro NakamuraDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
Anthony SteinDepartment of Hematology and HCT, City of Hope National Medical Center, Duarte, CA.
City Of Hope National Medical Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

backgroundMutations in isocitrate dehydrogenase (IDH)1/2 genes result in nicotinamide adenine dinucleotide phosphate-dependent reduction of α-ketoglutarate and formation of 2-hydroxyglutarate, which blocks normal cellular differentiation and promotes leukemogenesis. Nearly 20% of acute myeloid leukemia (AML) patients carry IDH1/2 mutations. Although multiple investigators have described the prognostic implications of IDH mutations in AML patients receiving chemotherapy, the effect of these mutations on outcomes after allogeneic (allo) hematopoietic cell transplantation (HCT) is unknown. PATIENTS AND

methodsWe report on the clinical outcome of a cohort of AML patients, who were tested for IDH mutations and underwent alloHCT at City of Hope (2015-2017). Of a total of 317 screened patients, 99 (31%) underwent alloHCT, of whom 23 carried and 76 did not carry IDH mutations (control).

resultsNo statistical significance was detected in patient's overall survival (P = .84). With a median follow-up of 7.8 months, 1-year relapse rate of 29% and 13% was seen in the IDH-mutated and control group, respectively (P = .033). IDH1/2 mutation status remained significantly associated with relapse (hazard ratio, 2.8; P = .046) after inclusion of pre-HCT disease status in a multivariable model.

conclusionOur results, despite low patient numbers, indicate that IDH mutations are associated with higher relapse rate after alloHCT. Further prospective studies on post transplantation IDH inhibition is required to improve outcomes in AML patients who carry IDH mutations.

Indexed as

Hematopoietic Stem Cell TransplantationMutationAdultAgedDisease ManagementFemaleGenetic Predisposition to DiseaseHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMiddle AgedPrognosisTransplantation, HomologousTreatment OutcomeIsocitrate DehydrogenaseAllogeneic HCTIDH1/2 mutationsRelapse rateRetrospective studySurvival

Identifiers

PMID31155409
PMCPMC9129101
OpenAlexW2941023504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.